# The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms

> **NCT07711444** · NA · COMPLETED · sponsor: **National Science and Technology Council, Taiwan** · enrollment: 54 (actual)

## Conditions studied

- COVID - 19
- Depression - Major Depressive Disorder

## Interventions

- **DIETARY_SUPPLEMENT:** Eicosapentaenoic acid (omega-3 fatty acid)
- **DIETARY_SUPPLEMENT:** Specialized Pro-Resolving Lipid Mediator
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT07711444
- **Lead sponsor:** National Science and Technology Council, Taiwan
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711444, "The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*